Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy
Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.
Authors
- Giulia Notini (ORCID: https://orcid.org/0009-0005-8379-1497)
- José Manuel Pérez-García (ORCID: https://orcid.org/0000-0003-4238-2046)
- Javier Cortés
- Giampaolo Bianchini
Institutions
- Vita-Salute San Raffaele University (IT)
- Hospital Universitario de Torrejón (ES)
- MedSIR (Spain) (ES)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1371/journal.pmed.1004930
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 24.20